Ulixacaltamide

A population estimate placed US essential tremor prevalence at approximately 7.01 million people in 2012, whereas a separate analysis estimated 1.1 million US adults with diagnosed essential tremor in 2024. These estimates use different ascertainment approaches and do not establish a temporal decline. Reported burdens include impaired daily activities, depression, anxiety, falls, sleep disturbance, and caregiver assistance. One claims analysis reported annual all-cause healthcare costs of $17,560 per person with essential tremor in 2019 US dollars, including $2,233 attributed to essential tremor. In a clinic-based cohort, approximately 25% required care partners, with reported caregiving averaging 24 to 44 hours weekly.

Essential3 Study 1 randomized 473 participants. At Day 56, mADL11 changed by -4.3 with ulixacaltamide and -1.7 with placebo in the mITT populations of 199 and 233 participants, respectively; the between-group difference was -2.57 points (95% CI, -3.62 to -1.53). Study 2 enrolled 238 participants and randomized 80 responders to continued treatment or placebo; 55% and 33%, respectively, maintained response. Drug-related adverse events led to discontinuation in 63 of 233 ulixacaltamide recipients (27.0%) versus 4 of 234 placebo recipients (1.7%) in Study 1, and 65 of 231 ulixacaltamide recipients (28.1%) in Study 2. Essential1 did not meet its primary endpoint (p=0.126); its TETRAS-ADL secondary result was nominally significant (p=0.026).

The phase 3 evidence supports short-term improvement in daily functioning versus placebo and maintenance of benefit during randomized withdrawal among selected responders. Treatment discontinuations, differential inclusion in the Study 1 mITT analysis, and the responder-enriched Study 2 design limit interpretation. Essential1 did not meet its primary endpoint. Ulixacaltamide remains investigational; the reported FDA target action date is January 29, 2027, rather than an approval date. Comparative effectiveness against established therapies and product-specific economic value remain undetermined in the evidence collected here.